Promise of factor Xa inhibition in acute coronary syndromes

Leong Lee; Derek Chew

doi:10.1007/s11886-011-0228-8

Promise of factor Xa inhibition in acute coronary syndromes

Leong Lee, Derek Chew

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Drugs that inhibit factor Xa have been shown to reduce mortality and morbidity in acute coronary syndromes (ACS). Presently, factor Xa inhibition is most often achieved indirectly with the heparins and, increasingly, fondaparinux. Despite effective anticoagulation with indirect factor Xa inhibition there remains considerable mortality and morbidity in ACS. The recently developed direct factor Xa inhibitors (the xabans) appear to offer promise as alternatives to the heparins. We review the evidence behind indirect and direct factor Xa inhibition in non-ST-segment elevation ACS, ST-segment elevation myocardial infarction, and with percutaneous coronary intervention.

Original language	English
Pages (from-to)	40-48
Number of pages	9
Journal	Current Cardiology Reports
Volume	14
Issue number	1
DOIs	https://doi.org/10.1007/s11886-011-0228-8
Publication status	Published - Feb 2012

Keywords

Acute coronary syndrome
Apixaban
Enoxaparin
Factor Xa
Factor Xa inhibition
Fondaparinux
Heparin
Low molecular weight heparin
NSTEACS
NSTEMI
Otamixaban
Rivaroxaban
STEMI
Unfractionated heparin
Unstable angina

Access to Document

10.1007/s11886-011-0228-8

Fingerprint Dive into the research topics of 'Promise of factor Xa inhibition in acute coronary syndromes'. Together they form a unique fingerprint.

Cite this

@article{a31578b8910745feb9c3ef4d227812fd,

title = "Promise of factor Xa inhibition in acute coronary syndromes",

abstract = "Drugs that inhibit factor Xa have been shown to reduce mortality and morbidity in acute coronary syndromes (ACS). Presently, factor Xa inhibition is most often achieved indirectly with the heparins and, increasingly, fondaparinux. Despite effective anticoagulation with indirect factor Xa inhibition there remains considerable mortality and morbidity in ACS. The recently developed direct factor Xa inhibitors (the xabans) appear to offer promise as alternatives to the heparins. We review the evidence behind indirect and direct factor Xa inhibition in non-ST-segment elevation ACS, ST-segment elevation myocardial infarction, and with percutaneous coronary intervention.",

keywords = "Acute coronary syndrome, Apixaban, Enoxaparin, Factor Xa, Factor Xa inhibition, Fondaparinux, Heparin, Low molecular weight heparin, NSTEACS, NSTEMI, Otamixaban, Rivaroxaban, STEMI, Unfractionated heparin, Unstable angina",

author = "Leong Lee and Derek Chew",

year = "2012",

month = feb,

doi = "10.1007/s11886-011-0228-8",

language = "English",

volume = "14",

pages = "40--48",

journal = "Current Cardiology Reports",

issn = "1523-3782",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Promise of factor Xa inhibition in acute coronary syndromes

AU - Lee, Leong

AU - Chew, Derek

PY - 2012/2

Y1 - 2012/2

N2 - Drugs that inhibit factor Xa have been shown to reduce mortality and morbidity in acute coronary syndromes (ACS). Presently, factor Xa inhibition is most often achieved indirectly with the heparins and, increasingly, fondaparinux. Despite effective anticoagulation with indirect factor Xa inhibition there remains considerable mortality and morbidity in ACS. The recently developed direct factor Xa inhibitors (the xabans) appear to offer promise as alternatives to the heparins. We review the evidence behind indirect and direct factor Xa inhibition in non-ST-segment elevation ACS, ST-segment elevation myocardial infarction, and with percutaneous coronary intervention.

AB - Drugs that inhibit factor Xa have been shown to reduce mortality and morbidity in acute coronary syndromes (ACS). Presently, factor Xa inhibition is most often achieved indirectly with the heparins and, increasingly, fondaparinux. Despite effective anticoagulation with indirect factor Xa inhibition there remains considerable mortality and morbidity in ACS. The recently developed direct factor Xa inhibitors (the xabans) appear to offer promise as alternatives to the heparins. We review the evidence behind indirect and direct factor Xa inhibition in non-ST-segment elevation ACS, ST-segment elevation myocardial infarction, and with percutaneous coronary intervention.

KW - Acute coronary syndrome

KW - Apixaban

KW - Enoxaparin

KW - Factor Xa

KW - Factor Xa inhibition

KW - Fondaparinux

KW - Heparin

KW - Low molecular weight heparin

KW - NSTEACS

KW - NSTEMI

KW - Otamixaban

KW - Rivaroxaban

KW - STEMI

KW - Unfractionated heparin

KW - Unstable angina

UR - http://www.scopus.com/inward/record.url?scp=84857638418&partnerID=8YFLogxK

U2 - 10.1007/s11886-011-0228-8

DO - 10.1007/s11886-011-0228-8

M3 - Article

VL - 14

SP - 40

EP - 48

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 1

ER -

Promise of factor Xa inhibition in acute coronary syndromes

Abstract

Keywords

Access to Document

Other files and links

Cite this